Understanding how tumor evolution differs across ancestries to improve cancer treatment
Official title: Simulating Ancestrally Unbiased Tumor Evolution To Interrogate Drug Resistance
Funded at University of California, San Francisco · NIH-10687776 · Data updated 2026-11-12
This study is looking at how tumors from cancer patients of different backgrounds behave differently and how that affects their treatment, especially for African-American men with prostate cancer, to help create better and more effective therapies for everyone.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | September 19, 2023 |
| Project end | August 31, 2026 |
| Funding year | 2023 |
| Award (this year) | $1,453,500 |
| NIH project number | 1DP2CA290244-01 |
| Project ID | NIH-10687776 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include cancer patients from diverse ancestral backgrounds, particularly those with prostate cancer.
✕Less likely to help
Patients who do not have cancer or those whose tumors do not exhibit significant molecular differences based on ancestry may not benefit from this research.
What this research studies
This research investigates the molecular differences in tumors among cancer patients of various ancestries, focusing on how these differences affect responses to therapies. By examining both genetic and non-genetic alterations, the study aims to develop better models for tumor evolution that are representative of diverse populations. The goal is to create therapies that are more effective for patients who are often underrepresented in current cancer research, particularly African-American prostate cancer patients who face higher risks of drug resistance and mortality.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments tailored to the unique molecular profiles of diverse patient populations.
How similar studies have gone: Previous research has shown that understanding molecular differences in tumors can lead to significant advancements in personalized cancer therapies, suggesting this approach has potential for success.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Bose, Rohit — University of California, San Francisco
- Study coordinator: Bose, Rohit
Related research
Other NIH-funded projects on the same topics.
-
How cancer cells use exosomes to evade the immune system
This study is looking at how cancer cells use tiny bubbles called exosomes to hide proteins that can keep your immune system from fighting the tumor, and by figuring this out, the researchers hope to help doctors understand why some people respond well to cancer treatments while others don’t, ultimately aiming to creat
-
Reducing harm from smoking using electronic cigarettes
This study is looking at whether using electronic cigarettes can be a safer option for people who smoke traditional cigarettes, by comparing the health effects and exposure to harmful substances between the two.
-
Understanding how knee pain and knee obesity and muscle loss affect knee osteoarthritis
This project looks at how knee swelling, excess knee fat, and muscle loss relate to pain and structural changes in knee osteoarthritis in adults.
-
Cutaneous opioid signals in skin inflammation
A mentor-identified clinician-researcher at UCSF is studying how natural skin opioids regulate itch and pain in inflammatory skin conditions like eczema and hidradenitis, with plans to map where these opioids come from and how they affect skin nerves.
-
Pooling international data to understand long-term bisphosphonate use and atypical femur fractures
This project combines large patient datasets from multiple countries to understand how long-term bisphosphonate use relates to rare hip and thigh bone fractures, helping doctors and patients make safer treatment choices.
-
Airway cell and immune cell talks in lung transplant failure
This grant tests how airway cells and immune cells interact to drive chronic rejection after lung transplant, with the goal of slowing or preventing scar-like damage.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.